|drug2717||Quality-of-Life Assessment Wiki||0.27|
|D008258||Waldenstrom Macroglobulinemia NIH||0.71|
|D007945||Leukemia, Lymphoid NIH||0.50|
|D020522||Lymphoma, Mantle-Cell NIH||0.50|
|D015451||Leukemia, Lymphocytic, Chronic, B-Cell NIH||0.41|
|D003141||Communicable Diseases NIH||0.10|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
|D018352||Coronavirus Infections NIH||0.02|
There are 2 clinical trials
This study is aimed to investigate the effect of Famotidine in the symptomatic recovery of the different degrees of COVID-19 patients. COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medication against it. Like other countries of the world, Besides antiviral drugs, immunosuppressive agents, and symptomatic therapy like H2 receptor blocker FAMOTIDINE came to limelight due to its role in reducing the symptoms of COVID-19 patients. The study will include COVID-19 participants to confirm by RT PCR or an HRCT chest. Detail history of each participant with comorbidity will be taken and will be examined carefully. Both the hospitalized and OPD patients will be enrolled in this study. Seriously ill patients who require ventilation will not be included in this study. The outcome of the Famotidine treatment will be evaluated and compared with a control group.
Description: The number of participants with "Symptomatic improvement" determined by the change of individual presenting symptoms of the COVID-19 disease. Major symptoms, fever, cough, respiratory distress, chest tightness, sore throat, and myalgia will be rerecorded daily. This will be done by the investigators in the case of the hospitalized patients and the patient itself by a daily self assessment cart in the case of OPD patients.Measure: Symptomatic improvement Time: Following randomization 10 days.
Description: The number of participants with "Clinical status (Stable or Deteriorate clinical state)" determined by the chart or the judgment of the investigators. This will be defined as OPD patients require hospitalization, Hospitalized patients require High Dependency Unit (HDU), and an HDU patient requiring Ventilator or Intensive care support.Measure: "Clinical status (Stable or Deteriorate clinical state)" Time: Following randomization 15 days.
Description: The number of participants with "adverse effects" determined by the existence of the pharmacological side effects of the particular drug (Famotidine) during treatment. The adverse effect will define as the symptoms expressed by the participants following the starting of the treatment other than the disease symptoms, those are within the proven/enlisted pharmacological side effects of the particular drug therapy. Adverse effects will be evaluated by the investigators during follow-ups or communication on phone or during the final collection of the recovery chart.Measure: Adverse effects Time: Following randomization 15 days.
Subjects with early symptoms of COVID19 take 1 or 2 20-mg [milligram] tabs/day of famotidine with 2000 IU vitamin D3 and 2 grams [2000 mg] vitamin C for 14 days. Consent, baseline, and follow-up after treatment are handled via internet. A 14-day extension of the higher dose plus the vitamins is allowed. Results on 216 subjects gives 80% power at p=0.05 if 22% get hospitalized with low-dose vs 7% with "high"-dose famotidine.
Description: "Did you feel worse?" (yes or no) and "Did you get hospitalized?" (yes or no)Measure: Negative outcome Time: "Since you started taking CDF..." (requested duration: 14 days)
Description: "Did you recover or improve from your symptoms?" (yes or no)Measure: Positive response Time: since you started taking CDF (for a nominal 14 days)
Description: Did you feel better after stopping study treatment, but then symptoms returned? (yes or no)Measure: Relapse Time: since you started taking CDF (for a nominal 14 days)
Description: Did you switch from plain vitamin C to ascorbyl palmitate or calcium ascorbate? (yes or no)Measure: tolerability of ascorbic acid Time: since you started taking CDF (for a nominal 14 days)
Description: If you got hospitalized, was it for COVID-19? (yes, no, or Not applicable. If you were hospitalized but not for COVID-19, please e-mail [sponsor] at email@example.comMeasure: Unexpected serious adverse event Time: within 35 days after you started taking CDF
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports